Jan 19 (Reuters) - Zealand Pharma A/S:
* ZEALAND PHARMA ANNOUNCES PROGRESS TO PHASE 3 WITH DASIGLUCAGON FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM IN FIRST HALF 2018
* ZEALAND PHARMA - U.S. FDA APPROVED ZEALAND‘S INVESTIGATIONAL NEW DRUG APPLICATION FOR INITIATION OF TWO PHASE 3 CLINICAL TRIALS OF DASIGLUCAGON IN CHI​ Source text for Eikon: Further company coverage:
 